Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2001 Jun;233(6):827-34.
doi: 10.1097/00000658-200106000-00013.

Attenuation of posttraumatic muscle catabolism and osteopenia by long-term growth hormone therapy

Affiliations
Clinical Trial

Attenuation of posttraumatic muscle catabolism and osteopenia by long-term growth hormone therapy

D W Hart et al. Ann Surg. 2001 Jun.

Abstract

Objective: To determine whether the beneficial effects of growth hormone persist throughout the prolonged hypermetabolic and hypercatabolic response to severe burn.

Summary background data: The hypermetabolic response to severe burn is associated with increased energy expenditure, insulin resistance, immunodeficiency, and whole body catabolism that persists for months after injury. Growth hormone is a potent anabolic agent and salutary modulator of posttraumatic metabolic responses.

Methods: Seventy-two severely burned children were enrolled in a placebo-controlled double-blind trial investigating the effects of growth hormone (0.05 mg/kg per day) on muscle accretion and bone growth. Drug or placebo treatment began on discharge from the intensive care unit and continued for 1 year after burn. Total body weight, height, dual-energy x-ray absorptiometry, indirect calorimetry, and hormone values were measured at discharge, then at 6 months, 9 months, and 12 months after burn. Results were compared between groups.

Results: Growth hormone subjects gained more weight than placebo subjects at the 9-month study point; this disparity in weight gain continued to expand throughout the remainder of the study. Height also increased in the growth hormone group compared with controls at 12 months. Change in lean body mass was greater in those treated with growth hormone at 6, 9, and 12 months. Bone mineral content was increased at 9 and 12 months; this was associated with higher parathormone levels.

Conclusions: Low-dose recombinant human growth hormone successfully abates muscle catabolism and osteopenia induced by severe burn.

PubMed Disclaimer

Figures

None
Figure 1. Study procedures during the year after burn. REE, resting energy expenditure; DEXA, dual-energy x-ray absorptiometry.
None
Figure 2. Lean body mass changes measured by serial dual-energy x-ray absorptiometry (DEXA) scans in the same children.
None
Figure 3. Bone mineral content changes in serial dual-energy x-ray absorptiometry (DEXA) scans from the same children.
None
Figure 4. Resting energy expenditure as a percentage of the predicted basal metabolic rate (BMR) over time in burned children treated with growth hormone or placebo.
None
Figure 5. Scatter plot of parahormone levels with and without growth hormone (GH) treatment in severely burned children.

References

    1. Moore FD. Response to starvation and stress. In: Moore FD, ed. Metabolic care of the surgical patient. Philadelphia: WB Saunders; 1959: 202–275.
    1. Warden GD, Heimbach DC. Burns. In: Schwartz SI, ed. Principles of surgery. New York: McGraw-Hill, Inc.; 1999: 232–254.
    1. Hart DW, Wolf SE, Mlcak R, et al. Persistence of muscle catabolism after severe burn. Surgery 2000; 128: 312–319. - PubMed
    1. Rutan RL, Herndon DN. Growth delay in postburn pediatric patients. Arch Surg 1990; 125: 392–395. - PubMed
    1. Cuthbertson DP, Shaw GB, Young FG. The anterior pituitary gland and protein metabolism. II. The influence of anterior pituitary extract on the metabolic response of the rat to injury. J Endocrinol 1941; 2: 468–474.

Publication types

MeSH terms